The KLF4 Knockout A2780 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population in the A2780 human ovarian adenocarcinoma epithelial cell line, featuring targeted disruption of the KLF4 gene. This heterogeneous knockout model provides a loss-of-function tool for investigating KLF4-dependent processes without monoclonal selection, enabling population-level analyses of transcription factor function in cancer biology.
A2780 is a widely used ovarian cancer cell line derived from an untreated patient with endometrioid adenocarcinoma. It serves as a standard model for studying drug sensitivity??particularly to cisplatin??and resistance mechanisms, retaining epithelial characteristics and relevant oncogenic signaling pathways critical for translational oncology research.
KLF4 encodes a zinc finger transcription factor that binds GC-rich and CACCC sequences to regulate genes governing proliferation, apoptosis, differentiation, and pluripotency. Its activity is modulated by upstream factors including OCT4, SOX2, MYC, TP53, and TGF???/SMAD signaling, and it directly controls expression of targets such as p21 (CDKN1A), cyclin D1 (CCND1), and E?cadherin (CDH1). KLF4 physically interacts with transcriptional coregulators like ???catenin (CTNNB1), HDAC1, PCAF, EP300, and KLF5, and participates in cross?talk among Wnt/???catenin, TGF???, PI3K/AKT, and p53 pathways. In A2780 cells, this network orchestrates cell cycle progression, epithelial integrity, and apoptotic responses, with context?dependent tumor?suppressive or oncogenic outcomes.
In the ovarian cancer context, KLF4 knockout in A2780 cells offers a platform to dissect its roles in proliferation, epithelial?to?mesenchymal transition (EMT), and drug sensitivity. Loss of KLF4 may disrupt transcriptional programs that control cisplatin response and metastatic potential, thus providing a model to study the molecular basis of acquired chemoresistance and tumor heterogeneity. The polyclonal format preserves editing diversity, mimicking intratumoral variation and supporting robust population-based assays.
Research applications include functional genomics screens, EMT investigations, and drug response profiling using techniques such as Western blotting, RT?qPCR, immunofluorescence, flow cytometry, colony formation, migration/invasion assays, viability assays, reporter assays, ChIP?qPCR, and RNA?seq. For further details, contact Ascent Research.
